Cholinesterase Inhibitory Potential of Quercetin towards Alzheimer’s Disease-A Promising Natural Molecule or Fashion of the Day?-A Narrowed Review


ERDOĞAN ORHAN İ.

Current Neuropharmacology, cilt.19, sa.12, ss.2205-2213, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 19 Sayı: 12
  • Basım Tarihi: 2021
  • Doi Numarası: 10.2174/1570159x18666201119153807
  • Dergi Adı: Current Neuropharmacology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE, Psycinfo
  • Sayfa Sayıları: ss.2205-2213
  • Anahtar Kelimeler: Quercetin, Alzheimer's disease, cholinesterase inhibition, bioavailability, neuroprotection, flavonoid, BLOOD-BRAIN-BARRIER, ACETYLCHOLINESTERASE INHIBITION, INDUCED NEUROTOXICITY, LEUCOJUM-AESTIVUM, SIGNALING PATHWAY, GENE-EXPRESSION, PHENOLIC-ACIDS, IN-SILICO, FLAVONOIDS, DISEASE
  • Gazi Üniversitesi Adresli: Evet

Özet

© 2021 Bentham Science Publishers.Natural substances are known to have strong protective effects against neurodegenerative diseases. Among them, phenolic compounds, especially flavonoids, come to the fore with their neuroprotective effects. Since quercetin, which is found in many medicinal plants and foods, is also taken through diet, its physiological effects on humans are imperative. Many studies have been published up to date on the neuroprotective properties of quercetin, a flavanol derivative. However, there is no review published so far summarizing the effect of quercetin on the cholinesterase (ChE) enzymes related to the cholinergic hypothesis, which is one of the pathological mechanisms of Alzheimer's Disease (AD). However, ChE inhibitors, regardless of natural or synthetic, play a vital role in the treatment of AD. Although the number of studies on the ChE inhibitory effect of quercetin is limited, it deserves to be discussed in a review article. With this sensitivity, the neuroprotective effect of quercetin against AD through ChE inhibition was scrutinized in the current review study. In addition, studies on the bioavailability of quercetin and its capacity to cross the blood-brain barrier and how this capacity and bioavailability can be increased were given. Generally, studies containing data published in recent years were obtained from search engines such as PubMed, Scopus, and Medline and included herein. Consequently, quercetin should not be considered as a fashionable natural compound and should be identified as a promising compound, especially with increased bioavailability, for the treatment of AD.